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Abstract
Multiple Myeloma (MM) is a lymphatic neoplasm characterized by clonal proliferation of malignant plasma cell that
eventually develops resistance to chemotherapy. Drug resistance, differentiation block and increased survival of the MM
tumor cells result from high genomic instability. Chromosomal translocations, the most common genomic alterations in
MM, lead to dysregulation of cyclin D, a regulatory protein that governs the activation of key cell cycle regulator – cyclin
dependent kinase (CDK). Genomic instability was reported to be affected by over expression of another CDK regulator -
cyclin E (CCNE). This occurs early in tumorigenesis in various lymphatic malignancies including CLL, NHL and HL. We
therefore sought to investigate the role of cyclin E in MM. CCNE1 expression was found to be heterogeneous in various MM
cell lines (hMMCLs). Incubation of hMMCLs with seliciclib, a selective CDK-inhibitor, results in apoptosis which is
accompanied by down regulation of MCL1 and p27. Ectopic over expression of CCNE1 resulted in reduced sensitivity of the
MM tumor cells in comparison to the paternal cell line, whereas CCNE1 silencing with siRNA increased the cell sensitivity to
seliciclib. Adhesion to FN of hMMCLs was prevented by seliciclib, eliminating adhesion–mediated drug resistance of MM
cells. Combination of seliciclib with flavopiridol effectively reduced CCNE1 and CCND1 protein levels, increased subG1
apoptotic fraction and promoted MM cell death in BMSCs co-culture conditions, therefore over-coming stroma-mediated
protection. We suggest that seliciclib may be considered as essential component of modern anti MM drug combination
therapy.
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Introduction
Multiple myeloma (MM) is a malignancy of antibody-secreting
B cells. Upon transformation plasma cells accumulate within the
bone marrow (BM). The symptoms of this disease relate to
anemia, immunosuppression, bone destruction, and renal failure
[1,2,3]. The disease is initially chemo-sensitive and may enter
dormant phases of variable duration. With time, it develops
independence from microenvironment-growth factors and resis-
tance to medication and apoptosis [4]. At this stage, malignant
cells may be propagated in vitro to produce human myeloma cell
lines (hMMCLs). Elucidation of the genetic events related to the
various stages of development is crucial to understanding the
pathogenesis of this disease.
Genetic profiling of MM tumor cells reveals karyotypic
instability which is characterized by aneuploidy including
hyperploidy, hypoploidy, trisomy or tetrasomy, monosomy or
nullosom as well as other chromosomal abnormalities such as
translocations, deletions, and amplifications [5–7]. High preva-
lence (37%) of near tetraploid plasma cells was detected in BM
samples from MM patients [7]. This instability is detected at the
earliest stages of the disease and increases to extreme genetic
abnormalities, similar to those observed for solid tumors [8].
The frequency and the extent of karyotypic abnormalities
correlate with the development of the disease and the response to
treatment. Abnormal karyotype is found in about 20% of patients
at stage I, 60% of patients at stage III, and more than 80% of
patients with an extramedullary tumor [6]. The karyotipic
anomalies in hMMCLs are greater than 90% [6].
Additionally, chromosome 13 abnormalities have been reported
to occur in MM and to have an unfavorable prognosis in MM
[5,9–11].
About 40% of MM tumors can be classified by commonly
observed mutations that include chromosomal translocations
involving the immunoglobulin gene (Ig) with 5 recurrent
chromosomal partners and oncogenes: 11q13 (CCND1); 4p16
(FGFR3 and MMSET); 6p21 (CCND3); 16q23 (MAF); and 20q11
(MAFB) [8]. Recently, a strong association between D13 and
translocation t(11;14) with deletions of the IgH was reported [12].
The high genetic heterogeneity which affects the disease initiation,
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in the treatment of MM.
Genomic instability was reported to be affected by over-
expression of cyclin E (CCNE). Cyclin E is the regulatory subunit
of Cyclin Dependent Kinase 2 (Cdk2), a heterodimer that
functions as a key regulator of cell cycle progression. This
heterodimer governs the G1-S boundary, where initiation of DNA
replication, S-phase specific transcription and centrosome dupli-
cation occur. Periodic expression at the G1-S boundary of cyclin E
is regulated by its transcription followed by rapid turnover [13,14].
Deregulation results in untimely expression of CCNE which may
induce genomic instability [15]. Indeed, its over expression is
detected as an early event in tumorgenesis of many solid tumors,
including breast, colon, and prostate carcinomas, as well as
hematologic malignancies like chronic lymphocytic leukemia and
Hodgkin’s and non-Hodgkin’s lymphoma [14,16,17]. As CCND
has been found to be overexpressed in more than 80% of MM
tumors [18], it may play a critical role in the development,
proliferation and survival of MM cells. Thus MM cells can serve as
good candidates for the examination of CDK inhibition.
The development of CDK inhibitors for chemotherapeutic use
has been a favorable target of the pharmacological industry [19].
Whereas, the first generation of such inhibitors had a broad range
of CDK targets, current development aims for more specific
inhibition and higher affinity compounds. Several such inhibitors
have been tested in-vitro in tumor cell lines and in-vivo in animal
models of various neoplasms [20]. MM has been found to be
sensitive to a range of CDK inhibitors [21–25]. Seliciclib
(Roscovitine, CYC202) a selective inhibitor of CDK’s has potent
cytotoxicity against MM cells [25,26]. The suggested mechanism
of action is modulation of MCL1 (an antiapoptotic protein in
myeloid cell leukemia) mediated by inhibition of IL-6 secretion in
the BM milieu [25,26]. Therefore, this inhibitor dually targets the
tumor cells as well as the microenvironment that supports its
growth. Currently there are several ongoing clinical trials utilizing
an oral formulation of seliciclib, the initial Phase I study reported a
stabilization of various solid tumors accompanied with grade 2–3
toxicities [27]. Seliciclib has been reported to inhibit CCND
expression [20,28] and therefore may have an additional
advantage in the treatment of MM that over express this protein
[18].
In this work we set out to determine the role of cyclin E in the
proliferation and survival of MM cells. We chose to conduct the
study on seven different hMMCL’s in order to signify the
heterogeneity of this disease. Our goals were: to determine the
expression profile of cyclin E; to assess the sensitivity of hMMCLs
to the CDK inhibitor seliciclib; to elucidate the mechanism of
seliciclib-induced-apoptosis and to explore the CDK-inhibition on
the adhesion of MM cell to an extracellular matrix (ECM).
Results
The Expression Profile of CCNE1 in Human MM Cell Lines
(hMMCLs)
Multiple myeloma displays a high genomic instability [8] which
is observed in other types of cancer and is known to be affected by
over-expression of cyclin E [14,16]. To determine the expression
profile of CCNE1 in hMMCLs, cells were extracted, and the level
of the protein verified by immunoblotting (Figure 1A). The levels
of CDK2 expression served as an internal control. CCNE1 was
detected mainly as a 50 kDa protein. Additional lower molecular
weight bands of 40 kDa, were observed in agreement with
previous studies [29].
Further analysis of the CCNE1 transcript level was carried out
by quantitative reverse transcription PCR (qRT-PCR) of RNA
that was extracted from free running hMMCLs. The levels of
CCNE1 transcript were compared to the level of GAPDH that
served as an internal control. The levels of protein and the
transcript were directly proportional (Figure 1B). We thus defined
the hMMCLs according to the level of CCNE1 expression: high
(U266 and NCI-H929) and low (CAG, RPMI8226 and ARP-1).
The plasma cell leukemia cell line ARH77 displayed high level of
CCNE1.
The Dependence of the Multiple Myeloma Cells Survival
on the CDK Activity
Previous studies have reported that hMMCLs are sensitive to
inhibitors of CDK. Seliciclib (Roscovitine, CYC202), is a selective
chemical inhibitor with potent cytotoxicity against MM cells
[25,26]. To determine its effect, six MM cell lines (NCI H929,
RPMI8226, CAG, ARP-1 and U266) and one plasma cell
leukemia cell line ARH77 were incubated in the presence of
either DMSO or increasing concentrations of seliciclib for 72
hours. The viability of the cells was determined by an MTT assay.
There was no difference in MTT incorporation between control-
untreated cells and DMSO-treated cells (data not shown).
Treatment with seliciclib resulted in dose-dependent cytotoxicity
(Figure 2A), with a calculated IC50 ranging from 20 to over
80 mM (Table 1). As demonstrated in Figure 2A, response of
hMMCLs to seliciclib correlated to CCNE1 expression levels.
High CCNE1-expressing NCI H929 and U266 cells revealed high
sensitivity to seliciclib, whereas low-CCNE1 cells (ARP-1, CAG
and RPMI8226) showed intermediate sensitivity. ARH77 cells
were different from the other cell lines and despite the high level of
CCNE1 were resistant to seliciclib.
To characterize the cytotoxic effect of seliciclib on MM cells, we
performed cell-cycle analysis on representative hMMCLs from
each category; similar results were obtained for all cell lines (data
not shown). Analysis of nuclear DNA distribution using flow
cytometry showed that in sensitive NCI H929 cells seliciclib
treatment augmented the fraction of hypoploid cells (subG1
cells),an established indication of apoptosis, resulting from
degradation and subsequent leakage of nuclear DNA from the
cells. An increase in the subG1 cell population following seliciclib
treatment was accompanied by a concomitant reduction in the
G0/G1 cell population. In contrast, the cell cycle distribution of
the resistant ARH77 cells was not affected by seliciclib (Figure 2B).
Statistical analysis of multiple experiments with two sensitive lines
(NCI H929 and ARP1) revealed a significant difference in the
fraction of apoptotic cells between control and seliciclib treated
cells (Figure 2C).
Further characterization was carried out by quantification of
annexin V binding as a marker for early apoptosis. The sensitivity
of the various hMMCLs strains varied from the resistant ARH77
line, to the highly sensitive NCI H929. The results for 2
representative cell lines are depicted in figure 3. Annexin V
binding was the same for control-untreated cells and DMSO-
treated cells (Figure 3A). Following seliciclib treatment the
sensitive line NCI H929 line showed an increased fraction of
annexin V positive cells, while the resistant line ARH77 showed no
annexin V binding (Figure 3A). Annexin V binding was detected
within 5 hours of seliciclib addition, and it reached a maximum
following overnight incubation (Figure 3A). Statistical analysis of
multiple experiments revealed a statistically significant induction of
apoptosis following seliciclib treatment (Figure 3B), only in the
sensitive line (p,0.05).
Heterogenic Expression of Cyclin E in MM
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the molecular level. This was achieved by analysis of the
expression of MCL1, an antiapoptotic BCL2 family member, that
is constitutively expressed in multiple myeloma cells [30]. To
determine the expression level of MCL1 in hMMCLs, cells were
extracted, and protein expression was verified by immunoblotting.
Interestingly, the basal level of MCL1 expression was considerably
lower in ARH77 in comparison to the other hMMCLs tested
(Figure 4A). This result suggests that other antiapoptotic BCL2
family member may play a role in the survival of this particular cell
line.
Incubation of the cells with seliciclib caused a remarkable
reduction of MCL1 expression for all hMMCLs tested (Figure 4B).
The reduction was time and dose-dependent (Figure 4C).
Careful analysis of the expression profile, following seliciclib
addition, revealed lower molecular forms of MCL1 possibly
reflecting hypo-phosphorylation (Figure 4C) in agreement with
previous studies [31].
To evaluate the effect of seliciclib on MCL1 phosphorylation in
hMMCLs we tested the levels of phosphorylated MCL1 in control
and seliciclib-treated cells using phospho-Ser159/Thr163 MCL-1
specific antibody. Indeed, MCL1 phosphorylation was remarkably
reduced following seliciclib treatment (Figure 4D). These results
clearly indicate the role of seliciclib in the loss of total and
phosphorylated MCL1 protein.
To further explore the seliciclib-induced down regulation of
MCL1 we incubated the cells in the presence of both seliciclib and
MG132, a potent proteasome inhibitor. Indeed, in the presence of
both inhibitors, the seliciclib-induced reduction of MCL1
expression was eliminated. The level of MCL1 was comparable
to control untreated cells (Figure 4E). Therefore we can conclude
that seliciclib leads to downregulation of MCL1 protein via
proteasome-mediated degradation.
The Effect of Seliciclib on the Cell Cycle Regulators
We were interested in examining the effect seliciclib has on the
expressionofbothcyclins:CCNDandCCNE1aswellasp27kip1,a
negative regulator of CDK’s. Initial analysis revealed a heteroge-
neous expression profile of the various hMMCLs (Figure 5A).
CCND2 was detected mainly as a 33 kDa protein with additional
highermolecularweightbands.WedefinedthehMMCLsaccording
tothelevelofCCND2expression:high(CAG,MM,NCI-H929,and
U266), medium (RPMI8226 and ARP1) and low(ARH77).
Comparison of the levels of CCND2 and CCNE1 expression
revealed variability between the different cell lines. Whereas all the
high CCNE1 expressing lines expressed high level of CCND2, the
Figure 1. CCNE1 expression profile in hMMCLS. (A) Various multiple myeloma cell lines (NCI H929, RPMI8226, CAG, ARP1 and U266) and plasma
cell leukemia cell line ARH77 in logarithmic growth phase were extracted and subjected to immunoblotting, utilizing CCNE1 antibodies. CDK2
expression served as an internal loading control. (B) Various multiple myeloma cell lines (NCI H929, RPMI8226, CAG, ARP1 and U266) and plasma cell
leukemia cell line ARH77 in logarithmic growth phase were extracted and subjected to qRT-PCR in quadruplicates. Data are represented as
mean6standard deviation of the ratio of CCNE1 and GAPDH between all hMMCLs and ARP1. (A–B) Experiments were performed at least 3 times and
one representative result is presented.
doi:10.1371/journal.pone.0033856.g001
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of CCND2.
The same heterogeneity was observed on the p27 protein
expression, some of the cell lines expressed high levels of the protein
(RPMI8226 and U266), while others expressed intermediate-low
levels (Figure 5A). Interestingly, an inverse relation was detected
between the level of CCNE1 and its inhibitor p27 in some of the
hMMCLs; high-CCNE1 expressing NCI-H929 had low levels of
p27 and low-CCNE1 RPMI8226 had high levels of p27.
Next, the effect of seliciclib on these key cell cycle regulators was
examined. Cells were incubated in the presence or absence of
seliciclib (50 mM) for 4 hours and the level of protein expression
was determined by immunoblotting. For comparison the levels of
CCND1 as well as CDK2 remained unchanged within each cell
line. Dramatic reduction in the level of CCND2 and p27 was
detected in all cell lines (basal levels of ARH77 were too low to
detect a decrease following inhibitor-treatment) (Figure 5B I). The
seliciclib-induced decrease in the level of CCND2 was dose and
time dependent (Figure 5C).
Figure 2. Heterogenous resistancy to seliciclib in hMMCLs. (A) The indicated hMMCLs were incubated in the absence or presence of
increasing concentrations of seliciclib for 3 days. Cell viability was determined by MTT assay. Data are represented as mean6standard deviation.
Experiments were performed at least 3 times and one representative result is presented. Seliciclib resulted in a decrease in cell viability with an IC50
ranging from 25 to 90 mM. (B) Cell cycle analysis by PI staining was performed on hMMCLs incubated in the absence or presence of 50 mM seliciclib
for 12 hours. Cells were collected, fixed, stained with propidium iodide (PI) and analyzed by flow cytometry. DNA distribution in the cells is presented.
(C) Quantification of cell cycle stage analysis of control and seliciclib-treated (50 mM, 12 hours culture) hMMCLs. Analysis of representative lines of
highly sensitive (NCI H929), a moderately-sensitive (ARP1) and a resistant (ARH77) lines are displayed. The subdyploid DNA peak (subG1) represents
apoptotic cell fraction. Data are represented as mean6standard deviation of 3 different experiments. Probability values of t-test are presented
**p,0.01.
doi:10.1371/journal.pone.0033856.g002
Table 1. Seliclib sensitivity in MMCLs.
MMCL IC50 (mM)
ARH77 84
ARP1 32
CAG 33
MM 38
NCI H929 24
RPMI 8226 33
U266 26
Various multiple myeloma cell lines (NCI H929, RPMI8226, CAG, ARP1 and U266)
and plasma cell leukemia cell line ARH77 were incubated in the absence or
presence of increasing concentrations of seliciclib for 3 days. Cell viability was
determined by MTT assay. The calculated average value of IC50 of at least 3
experiments is presented.
doi:10.1371/journal.pone.0033856.t001
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migrating bands reflecting post-translational modifications. Phos-
phorylation of CCNE1 on Ser-399 by CDK2 was reported to
accelerate degradation via the ubiquitin proteasome pathway [32].
Short exposure to seliciclib did not affect the levels of the full-
length p50 form of CCNE1. However, the faster migrating bands
of CCNE1 disappeared in seliciclib-treated cells suggesting that
CCNE1 was not phosphorylated in the presence of CDK
inhibitor, whereas the level of non-phosphorylated CCNE1
remained unchanged following 4 hours of seliciclib treatment
(Fig. 5B I). It is conceivable that the seliciclib-induced decrease in
p27 levels may lead to subsequent stabilization of CCNE1. To test
this hypothesis, we evaluated CCNE1 levels following prolonged
(16 h) exposure to seliciclib. Indeed, significant increase in the
level of CCNE1 was detected after a long incubation period with
seliciclib (Figure 5 B II).
To further elucidate the possible effect of seliciclib on CCNE1
phosphorylation we evaluated the levels of phosphorylated
CCNE1 in seliciclib-treated hMMCLs. We observed a decrease
in CCNE1 phosphorylation following short (4 h) seliciclib
treatment, whereas total levels of CCNE1 were not significantly
affected by seliciclib (Figure 5C).
To explore the seliciclib-induced down regulation of p27 we
incubated the cells in the presence of both seliciclib and MG132.
In the presence of both inhibitors, the seliciclib-induced decrease
in p27 expression was eliminated, with a pattern similar to MCL1
expression response (Figure 4E). These results suggest that the
seliciclib-induced apoptosis is accompanied by down-regulation of
p27, as well as MCL-1 protein via the proteasome-mediated
degradation pathway, decrease of phosphorylated CCNE1 level
and stabilization of total CCNE1.
Combination of Seliciclib with Flavopiridol Elicits
Enhanced Anti-myeloma Activity
To further explore the role of CDK in hMMCLs survival and
the expression of cell cycle regulators we combined seliciclib
treatment with flavopiridol in order to achieve a more prominent
CDK inhibition. Flavopiridol is a semisynthetic flavonoid that
Figure 3. Seliciclib induces apoptosis in sensitive hMMCLs. hMMCLS were incubated in the absence or presence of 50 mM seliciclib. Following
5 hours or 16 hours of culture cells were collected, fixed, stained using annexin V/PI and analyzed by flow cytometry. The extent of apoptosis is
expressed as a percentage of cells positively stained using annexin V. (A) Seliciclib-sensitive NCI H929 and seliciclib-resistant ARH77 were incubated in
the presence or absence of seliciclib for the indicated time points. Experiments were performed at least 3 times and one representative result is
presented. (B) Representative analysis of seliciclib-induced apoptosis following a 16 hour incubation time in control, DMSO and seliciclib treated cells.
The percentage of live (annexin V/PI-negative) and apoptotic (annexin V-positive) cells is given. Data represents the mean and standard deviation of3
different experiments. Probability values of t-test are presented *p,0.05 **p,0.01.
doi:10.1371/journal.pone.0033856.g003
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effectively promotes tumor cell apoptosis [33] and was the first
CDK inhibitor to enter clinical trials [34]. We combined low doses
of flavopiridol (100 ng/ml) with low doses of seliciclib (10–20 mM)
and evaluated the effect of combined treatment on hMMCLs
viability. As shown in figure 6A, combination of the two CDK
inhibitors significantly reduced the number of viable cells in
culture, in comparison to each inhibitor alone. Furthermore,
combination of seliciclib with flavopiridol resulted in increased cell
cycle alterations and apoptosis in hMMCLs (Figure 6B). Combi-
nation of both agents effectively increased the subG1 (apoptotic)
population, accompanied by subsequent decrease in the percent-
age of G2/M cells (Figure 6C). Maximal combined effect on
apoptosis induction was achieved in seliciclib-sensitive NCI H929
and CAG cells. In NCI H929 cells combined treatment resulted in
63% of subG1 cells, vs.3.2% in control cells, 11% induced by
seliciclib (10 mM) alone and 20% induced by flavopiridol (100 ng/
ml) alone. In CAG cells the combined treatment yielded similar
results, showing 62% of subG1 cells, whereas seliciclib and
flavopiridol alone resulted in 10% and 17% subG1 cells,
respectively (Figure 6C). In contrast, seliciclib-resistant ARH77
cells did not respond to low concentrations of seliciclib and
flavopiridol, demonstrating only a mild increase in subG1
population following combined treatment (2.7% in control, 6%
in seliciclib- and 5.5% in flavopiridol-treated cells vs. 11% in the
combined protocol). Notably, elevated dose of flavopiridol
(500 ng/ml) increased the apoptosis of ARH77 cells, yielding
21% of subG1 population when applied alone and 35% of subG1
cells in combination with 10 mM of seliciclib (data not show).
Moreover, by combining flavopiridol with seliciclib we were able
to show effective decrease in CCND1 and CCNE1 expression,
evaluated by immunoblotting (Figure 6D). The most prominent
effect of the combined treatment on CCND1 expression was
detected in ARH77 and NCI H929 cells. Importantly, flavopiridol
treatment efficiently decreased the basal and seliciclib-induced
levels of CCNE1 in MM cells. These results may explain the
mechanism of the observed increased toxicity induced by the
combination of seliciclib with flavopiridol. All together, these data
Figure 4. Seliciclib downregulates MCL1 expression in hMMCLs. (A) The indicated multiple myeloma cell lines in logarithmic growth phase
were extracted and subjected to immunoblotting, utilizing MCL1 antibodies. In all experiments CDK2 expression serves as an internal loading control.
Experiments were performed at least 3 times and one representative result is presented. (B–C) MCL1 downregulation by seliciclib. Cells were
extracted and subjected to immunoblotting. (B) Various hMMCLs were incubated in the presence of seliciclib 50 mM or DMSO for 6 hours and the
level of MCL1 expression was analyzed. (C) RPMI8226, CAG and NCI H929 cells were incubated in the absence or presence of seliciclib 50 mM for the
indicated time points, or in the presence of increasing concentrations of seliciclib for 8 hours. (D) Reduction in MCL1 phosphorylation by seliciclib.
Cells were treated with 50 mM or DMSO for 8 hours and the levels of total and phosphorylated MCL1 were analyzed by immunoblotting using specific
antibodies. b-actin was used to confirm equal protein loading. (E) CAG cells were incubated in the absence or presence of seliciclib or MG132 (10 mM)
exclusively or combined. MCL1 level of expression was verified by immunoblotting. b-actin was used to confirm equal protein loading.
doi:10.1371/journal.pone.0033856.g004
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apoptosis and reduces expression of cell cycle regulators in
hMMCLs.
Over-expression and Silencing of CCNE1
In light of the heterogeneity in CCNE1 level of expression in the
various hMMCLs, we were interested in exploring the effect over-
expression of CCNE1 may have on the sensitivity to CDK
inhibitors. To this end, we chose a low CCNE1-expressing
hMMCL RPMI8226 and stably transfected it with a CCNE1
expressing plasmid, stable clones have been selected by addition of
G418. The selected clones expressed an increased level of CCNE1
in comparison to the cells transfected with vector only (Figure 7A).
The level of expression was moderate and was comparable to NCI
H929 cells expressing constitutive high endogenous level of the
protein. Similar increase in CCNE1 level of transcript was
detected by qRT-PCR in the transfected cells (Figure 7B).
We then addressed the effects over-expression of CCNE1 may
have on sensitivity to seliciclib. Several clones stably expressing
CCNE1 were incubated in the absence or presence of increasing
concentrations of seliciclib for 72 hours and assayed for cell
viability by MTT assay. Figure 7C depicts that the cells exhibited a
decreased sensitivity to the drug as compared to the paternal cell
line RPMI8226.
To further investigate the role of CCNE1 levels in sensitivity to
CDK inhibition with seliciclib, we silenced CCNE1 expression in
high CCNE1-expressing seliciclib-resistant ARH77 and low
CCNE1-expressing seliciclib-sensitive RPMI8226 cells using
CCNE1 siRNA. Cells were electroporated with control non-target
siRNA or specific anti-CCNE1 siRNA and significant reduction
(more than 70% comparing to control) in CCNE1 protein levels
was observed following 48 hours in both cell lines, verified by
immunoblotting (Figure 8A, B). Next, we exposed control and
CCNE1-silenced cells to elevated concentrations of seliciclib for 48
hours and evaluated the viability using MTT. Cells with silenced
Figure 5. Effect of seliciclib on cell cycle regulators expression in hMMCLs. (A) The indicated multiple myeloma cell lines in logarithmic
growth phase were extracted and subjected to immunoblotting, utilizing CCND2, CCNE1 and p27 antibodies. b-actin expression serves as an internal
loading control. (B) Seliciclib effect on CCNE1, phosphor-CCNE1, CCND2, CDK2 and p27 expression: the indicated hMMCLs were incubated in the
presence or absence of 50 mM seliciclib for 4 (I) or 16 (II) hours. Control cells were incubated in the presence of DMSO. Cells were lyzed and extracts
were subjected to immunoblotting, utilizing specific antibodies. (C) CAG and NCI H929 cells were incubated in the absence or presence of increasing
concentration of seliciclib for over-night incubation or in 50 mM selicicilb for the indicated time points. Cells were lyzed and extracts were subjected
to immunoblotting, utilizing CCND2 and CDK2 antibodies. Control cells were incubated in the presence of DMSO. Experiments were performed 3
times and one representative result is presented. (D) CAG cells were incubated in the absence or presence of seliciclib or MG132 (10 mM) exclusively
or combined. p27 level of expression was verified by immunoblotting. b-actin was used to confirm equal protein loading.
doi:10.1371/journal.pone.0033856.g005
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control cells (Figure 8C).
These results suggest that expression levels of CCNE1 are able
to alter the sensitivity of hMMCLs to seliliclib-induced apoptosis.
Cell Adhesion and CDK Activity
Cytotoxic activity against multiple myeloma is known to be
hampered by various mechanisms resulting in drug resistance.
Adhesion to extracellular matrices, including fibronectin (FN) has
been associated with cell-adhesion-mediated drug-resistance
(CAM-DR) [35,36]. As MM cells are embedded in the bone-
marrow and rely on stromal microenvironment for their survival,
such mechanisms of CAM-DR are of high significance in treating
MM. We therefore investigated the effect of seliciclib on cell
adhesion to FN. Cells were pre-incubated for one hour, in the
absence or presence of increasing concentrations of seliciclib,
following which they were subjected to cell adhesion assay.
Seliciclib reduced the adhesion of high adhesive cells ARH77 as
well as medium adhesive cells NCI H929 (Figure 9A). Similar
results were obtained with all the hMMCLs (data not shown).
These results show that seliciclib has a direct inhibitory effect on
adhesion and displays an additional advantage as a chemother-
apeutic drug.
Since cell adhesion is known to render cells insensitive to
cytotoxic drugs by mechanisms of CAM-DR [36] we wanted to
explore the cytotoxic effect of seliciclib on adherent cells. Cells
were seeded onto FN or BSA coated 96 well plates and cell
viability was assayed 72 hours after the addition of increasing
Figure 6. Effect of seliciclib anf flavopiridol combined treatment on hMMCLs viability, cell cycle distribution and cyclin expression.
(A) The indicated myeloma cell lines were incubated in the absence or presence of 20 mM seliciclib, 100 ng/ml flavopiridol or combination of both
agents for 2 days. Cell viability was determined by MTT assay. Data are represented as mean6standard deviation. Probability values of t-test are
presented **p,0.01. (B–C) Cell cycle analysis by PI staining was performed on ARH77, RPMI8226, NCI H929 and CAG cells cultured in the absence or
presence of 10 mM seliciclib, 100 ng/ml flavopiridol or combination of both agents for 2 days. (B) Representative cell cycle distribution in NCI H929
cells, treated with seliciclib, flavopiridol or their combination. (C) Combined treatment with seliciclib and flavopiridol increases subG1 and decreases
G2/M fractions in hMMCLs. Data are represented as mean6standard deviation. Probability values of t-test are presented **p,0.01. (D) Effect of
seliciclib and flavopiridol on CCND1 and CCNE1 expression. Cells were incubated in the presence of 25 mM seliciclib, 100 ng/ml flavopiridol or
combination of both for 8 hours. Cells were lyzed and extracts were subjected to immunoblotting, utilizing CCND1 and CCNE1 antibodies. b-actin
was used to confirm equal protein loading.
doi:10.1371/journal.pone.0033856.g006
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FN-adhesion against doxorubicin, a known drug that is displays
CAM-DR (data not shown), there was no significant difference
between the cytotoxic effect of selicicilib on FN-adherent cells and
suspended cells (Figure 9B).
In addition, we evaluated the anti-myeloma effect of seliciclib in
combination with doxorubicin. Cells were treated with low
concentrations of seliciclib (20 mM for ARH77 and RPMI8226
cells and 10 mM for NCI H929 and CAG cells) and 10 ng/ml of
doxorubicin during 48 hours, viability was tested by MTT.
Significant increase in cell cytotoxicity was observed following
combined seliciclib-doxorubicin treatment (Figure 9C).
We next examined the effect of doxorubicin and flavopiridol,
each agent alone or in combination with seliciclib, on hMMCLs
co-cultured with bone marrow stromal cells (BMSCs). As shown in
Figure 9D, BMSCs protected myeloma ARH77 and NCI H929
cells from doxorubicin-induced cytotoxicity. Seliciclib effectively
targeted myeloma cells in the presence of BMSCs. However, in co-
culture with BMSCs same doses of seliciclib were not potent
enough to overcome the stroma-induced doxorubicin resistance in
both ARH77 and NCI H929 cells. In contrast to doxorubicin
treatment, combination of seliciclib with flavopiridol efficiently
reduced the viability of myeloma cells in co-culture conditions,
successfully overcoming the protective effect of stroma (Figure 9D).
Taken together these results indicated that MM are sensitive to
seliciclib regardless of their adhesive property. Moreover, adhesive
cells are not rendered resistant to seliciclib and do not display
CAM-DR, due to the direct prevention of cell adhesion by the
drug. Combination of seliciclib with another CDK inhibitor
flavopiridol may effectively overcome stroma-mediated resistance
and therefore serve as possible anti-myeloma therapeutic strategy.
Discussion
Proliferation of any given cell is tightly regulated by progression
through checkpoints located at the boundaries of cell cycle stages.
Progression through each phase of the cell cycle is controlled by
the activity of different cyclin-dependent kinases (CDKs) which are
heterodimers of a regulatory kinase coupled with a cyclin
regulatory subunit [37]. The Cyclin level of expression oscillates
throughout the cell cycle, enabling the timely coupling of the
distinct dimers. The association of CDK4 or CDK6 with D-type
cyclins is critical for the G1 phase progression, whereas the
CDK2-cyclin E complex is important for initiation of the S phase
[38]. Deviation from the orderly control can and does lead to a
neoplasm [19]. The most common translocations in multiple
myeloma, lead to dysregulation of CCND, an over-expression with
yet unknown biological significance [18]. The profile of CCNE1 in
MM and its involvement in this disease are the focus of the current
Figure 7. CCNE1 over-expression. RPMI8226 a low-CCNE1-expressing cell line was stably transfected with pRCCMV2hCyclin E1. (A) Stable clones
have been selected by addition of G418, and cell extracts of selected cloned were subjected to immunoblotting, utilizing CCNE1 antibodies. CDK2
expression serves as an internal loading control. (B) Stable clones have been selected by addition of G418, and cell extracts of selected cloned were
subjected to qRT-PCR. Presented is the relative amount of CCNE1 as compared to the levels of GAPDH. Data are represented as mean6standard
deviation. (C) CCNE1-overexpressing stable cell lines as well as paternal cell line were incubated in the absence or presence of increasing
concentrations of seliciclib for 3 days. Cell viability was determined by MTT assay. Data are represented as mean6standard deviation. Experiments
were performed twice and one representative result is presented.
doi:10.1371/journal.pone.0033856.g007
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expression in various MM cell lines. We show that ectopic over-
expression of this protein promotes the MM cell resistance to
seliciclib, a CDK inhibitor with high affinity towards CDK2/
CCNE, whereas CCNE1 silencing with siRNA increases the cell
sensitivity to seliciclib. This inhibitor is currently under phase II
clinical trials. We also discovered an additional potential benefit of
seliciclib, namely that it inhibits cell adhesion.
The expression of cyclin E is controlled by both transcriptional
and post-translational levels of regulation. At the transcriptional
level CCNE1 is directly regulated by E2F, which is sequentially
regulated by CCND and CCNE1 through the removal of the
inhibitory regulation of pRb [39,40]. At the post-transcriptional
level CCNE1 is regulated by several means: binding to CDK,
autophosphorylation and degradation. The CCNE stability is
regulated by its binding to CDK which protect the protein from
degradation. Only the monomeric cyclin is degraded. Upon
binding to CDK, CCNE undergoes phosphorylation on 2 specific
degron motifs [32] which results in binding of an additional
ubiquitin ligase Fbw7 unit [41]. Ubiquitination and proteosomal
degradation follow and lead to downregulation of CCNE and
CDK activity.
It is evident that this meticulous regulation of the stability of
CCNE is critical for a normal cell cycle progression. Indeed,
accumulation of CCNE either by over-expression or by defective
degradation is observed in several types of cancer amongst which
are breast, lung, cervix, endometrium, gastrointestinal tract,
sarcomas and hematological malignancies such as lymphoma
and leukemia (reviewed by Hwang et al.) [38]. Moreover, CCNE1
expression was found to be a prognostic marker related to the
clinical outcome. High expression, as detected by western blotting,
correlates with worse patient outcome for breast, small cell lung
carcinoma, squamous cell carcinoma of the larynx and adenocor-
tical tumors. Notwithstanding the prognostic value of CCNE1, its
significance as a single event in the progression of a neoplasm
needs to be established. We found high expression of CCNE1 in
several multiple myeloma cell lines at the level of the transcription.
Interestingly, we did not find a direct correlation between the
levels of CCND and CCNE1, namely cells such as NCI H929
express high level of both proteins whereas ARP1 and CAG that
express that same level of CCND express low levels of CCNE1. As
CCND expression is unregulated in most MM patients [42], E2F
is positively regulated and hence the CCNE1 levels of expression
are expected to increase. This discrepancy could be explained if
various regulatory mechanisms of transcription inhibition and/or
enhanced degradation pertain. The elucidation of these mecha-
nisms should be addressed of future studies.
Oscillation of the regulatory cyclin is one level of CDK
regulation, further regulation is brought about by a family of
CDK-inhibitors; these proteins bind to and inhibit the kinase
activity of the CDK. Altered expression of p27kip, a member of
the CDK inhibitor family, has been shown to accompany cancers,
via various mechanisms of impaired synthesis, accelerated
degradation and mislocalization [43]. p27kip1 has been reported
Figure 8. CCNE1 silencing. ARH77 and RPMI8226 cells were transfected with control or CCNE1 siRNA (500 nM) using electroporation. (A) 48 hours
following the transfection the cells were lyzed and subjected to immunoblotting, utilizing CCNE1 antibody. b-actin was used to confirm equal protein
loading. (B) Quantification of CCNE1 protein levels 48 hours post transfection using TINA software. Data represents the mean and standard deviation
of two different experiments. Probability values of t-test are presented **p,0.01. (C) At 48 hours following the transfection the cells were treated
with seliciclib (10–40 mM) for additional 48 hours. Viability was determined using MTT assay. Data are represented as mean6standard deviation
(**p,0.01). Experiments were performed twice and one representative result is presented.
doi:10.1371/journal.pone.0033856.g008
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expression in normal plasma cells, reflecting the importance of a
balanced CDK activity in the proper cell cycle [37,44].
We show an inverse relation between the expression levels of
CCNE1 and p27, which correlates to the interdependence of both
proteins [45]. Whereas, binding of p27 inhibits CDK activity but
promotes CCNE1 stability; phosphorylation of p27 by CDK2/
CCNE1 stimulates its ubiquitination by the SCF-Skp2, leading to
its proteasomal degradation [46,47].
Pharmaceutical Inhibition of CDK
CDKs have a central role in cell cycle progression and have
been for long a desired target for chemotherapeutic inhibition
[19]. This notion was fortified when tumor cells were found to be
more sensitive to the inhibitors than normal cells allowing for
selective destruction of neoplasmic cells.
The lack of toxicity in normal cells may be explained by the
unforeseen findings that CDK2, CDK4 and CDK6 are dispens-
able for normal mouse development. Knock-out mice of each
CDK are viable and display normal cell cycle progression,
revealing the dispensability and redundancy of these kinases.
Therefore in normal conditions, inhibition of a specific CDK may
be compensated by the activity of other CDKs.
Multiple myeloma has been found to be sensitive to CDK
inhibition by various chemical inhibitors including flavopiridol
[21,22], SNS-032 [24,48], P276-00 [25] and seliciclib [26].
Incubation of hMMCLs with these chemical induce cell cycle
arrest and apoptosis. The mechanism underlying the apoptotic
death of MM cells was found to be the downregulation of an anti-
apoptotic protein MCL1 [21,22,25,26]. Our results confirm the
above and show downregulation of MCL1 that precedes the cell
death induced by CDK inhibition. Transcription of MCL1 was
shown to be reduced by CDK inhibition due to suppression of
RNA polymerase II [21,22,24–26].
We provide evidence that in addition to the previously reported
inhibition of transcription, post-translational modification of
MCL1 renders its stability and targets it for protein degradation.
Upon selcliclib treatment, MCL1 separation on SDS-PAGE
Figure 9. Seliciclib effect on adhesion and cytotoxicty. (A) The indicated cells were pre-incubated in the absence or presence of increasing
concentrations of seliciclib for one hour, following which the cells were plated onto 40 mg/ml fibronectin coated plates. Following one hour
incubation, suspended cells were removed by repeated washes. Quantification of the adherent cells was performed by crystal violet staining. Data are
represented as mean6standard deviation. (B) The indicated cell lines were allowed to adhere to 40 mg/ml FN-coated plates for one hour, following
which they were exposed to increasing concentrations of seliciclib for three days. Cell viability was determined by MTT assay. Data are represented as
mean6standard deviation. (A–B) Experiments were performed at least 3 times and one representative result is presented. (C) ARH77 and NCI H929
were incubated in the absence or presence of BMSCs, treated with seliciclib (10 mM for NCI H929 and 20 mM for ARH77), doxorubicin (10 ng/ml),
flavopiridol (100 ng/ml) or combinations during 48 hours. Cell viability was determined by MTT assay. Signal produced by BMSCs alone was
subtracted as background.
doi:10.1371/journal.pone.0033856.g009
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found between the stability of MCL1 and its phosphorylation.
Whereby, MCL1 undergoes distinct phosphorylation events at the
PEST region (Thr 163), which protects it from rapid degradation
[31]. In this study, treatment with seliciclib yielded a dephosphor-
ylated form of MCL1 which was easily degradable and was
therefore present at reduced levels. Furthermore, we observed
significant decrease in phosphorylated MCL1 levels following
seliciclib treatment, detected by specific anti-phospho-MCL1
(Ser159/Thr163) antibody. We show that inhibition of protea-
some degradation indeed results in accumulation of MCL1. It is
interesting to note that in spite of stabilized MCL1, the inhibition
of proteasomal degradation by seliciclib induces apoptosis in MM
cells [49].
Plasma cell leukemia cell line ARH77 had undetectable levels of
MCL1 even prior to CDK-inhibition, suggesting an additional
mechanism of cell death induction alongside MCL1 downregula-
tion. An additional antiapoptotic protein, XIAP was found to be
sensitive to CDK inhibition in Chronic Lymphocytic Leukemia
(CLL) [50]. It would be interesting to verify whether XIAP is
expressed in ARH77 and is regulated by seliciclib treatment.
In addition to the downregulation of MCL1, we report on down
regulation of p27 by CDK inhibition. It is of interest that in
p27–/– fibroblasts, the rate of apoptosis is markedly increased
[51]. Restoration of p27 expression rescued the cells from
apoptosis. Therefore, the reduction in p27 amount, reported
herein can lead to the increased seliciclib-induced apoptosis.
An opposite effect of seliciclib on p27 was reported in a
xenograft model of breast cancer. Seliciclib arrested the cells at the
G2-M phase concomitant with an increase in the expression of
p27 [52]. The explanation for this discrepancy possibly lies in the
stage of cell cycle arrest and the corresponding active CDK.
Where the active heterodimers in G2-M phase are cyclin A/B
CDK 1 and in S-phase cyclin E CDK2, all of which are sensitive
for seliciclib.
CCND Over-expression and CCNE
The effect of CCNE1 heterogeneity on seliciclib-sensitivity
revealed that over-expression of CCNE1 in a low-expressing cell
line resulted in increased resistance to the inhibitor. This possibly
can be explained by the higher level of active heterodimres, hence
the need for more inhibitor. Interestingly, ectopic expression of
CCND1 in hMMCL U266 resulted in higher sensitivity to CDK
inhibition albeit a slightly lower expression of the protein [53]. The
ectopic expression was accompanied with a change in the cell cycle
distribution of the cell population - an increase in S-phase fraction
that was insensitive to CDK inhibition, possibly through the
prevention of E2F inactivation. This enhanced entry into S-phase
under CDK inhibition mediates the increased lethality. The
difference between these results and ours could reflect the higher
affinity of seliciclib to CDK2/CCNE1 than to CDK4/CCND1, as
well as the different cell lines tested, the CCND1 over-expression
was tested in U266 and whereas the CCNE1 in RPMI8226. These
cells express CCNE1 in an opposite manner whereby U266
expresses high level and RPMI8226 low levels of the protein.
A note of precaution, as there was no correlation in hMMCLs
between the level of endogenous expression of CCNE1 and the
sensitivity to seliciclib, its levels cannot predict the sensitivity of
MM cells to the drug. The complexity of cell cycle regulation in
the intact cell, namely heterogenic expression of CCNE1 is not the
only parameter that differs between the different patients.
Similarly, a recent study utilizing a novel CDK inhibitor P276-
00, over-expression of CCND1 resulted in increased resistance to
the drug, though there was no correlation to levels of endogenous
CCND expression in numerous MMCLs [25].
We and others present data that CDK inhibition downregulates
CCND2, interestingly, this effect is not collective to all hMMCLs.
CCND2 was downregulated by flavopiridol in ARP1 and ANBL-
6 cell lines but not in RPMI8226 [21]. In an additional study
CCND1 was the isoform that was sensitive to CDK inhibition,
seliciclib resulted in a decrease in its expression in colon cancer
cells [28]. It may be different in the case of MM cells, as CCND1
is over-expressed due to t(11;14) (q13;q32) translocation in MM
plasma cells and therefore may be free of CDK regulation.
However, we revealed that CCND1 and CCNE1 were reduced in
the presence of flavopiridol, and in some cell lines addition of
seliciclib in combination with flavopiridol further decreased
CCND1 and CCNE1 levels.
In contrast to the seliciclib-mediated down regulation of MCL-1
and CCND2, we report of marked increase in CCNE1 expression
following prolonged seliciclib treatment. The direct reason for the
accumulation of CCNE1 may be the elimination of the negative
auto regulatory loop, whereby CDK2 phosphorylates CCNE and
targets it for ubiquitination and degradation [32]. There may be
an additional correlation between the increased CCNE1 expres-
sion and seliciclib-induced apoptosis, a striking increase in
apoptosis was also reported in transgenic mice that overexpress
CCNE due to elimination of 2 degron signals of CCNE and its
accumulation [54]. Consistent with these data, substantial
induction of CCNE1 protein and CCNE1/CDK2 kinase activity
in multiple myeloma and lymphoma cells following radiation was
demonstrated [55]. This increase of CCNE levels might be
implicated in the initiation phase of apoptosis, therefore proposing
a dual role of CCNE1 in apoptosis of hematopoietic cells [13].
Adhesion
Normal plasma cells as well as malignant ones reside mainly in
the bone marrow [4], this strict location is maintained by cellular
crosstalk between the PC and BM cells, as well as factors within
the BM such as cytokines, chemokines and growth-factors.
The chemokine receptor CXCR4 and its chemokine SDF-1
ligand mediate homing to the BM [4]. BM setting is also regulated
through the interaction of adhesion receptors and their cognate
ligands on BM cells and extracellular matrix, the most prominent
component of which is fibronectin (FN). We as well as others show
that this adhesion is dependent on VLA-4 and that it correlates
with its level of expression [35,56,57]. Adhesion of tumor cells is
known to confer cell-adhesion-mediated-drug-resistance (CAM-
DR) that pose therapeutic obstacles in several neoplasms including
MM [36,58]. Therefore, interfering with cell adhesion has been a
desired target for increasing cytotoxicty of various chemothera-
peutic drugs. Recently, adhesion of MM cells was linked to
enhanced STAT-3 mediated IL-6 signaling, supporting further the
survival and proliferation of the tumor [59]. We present data
adding an advantage to the known effect of seliciclib as an anti
MM treatment. Seliciclib cytotoxic effects were comparable
whether cells were incubated on FN or BSA, namely there was
no CAM-DR. Furthermore, we show that cell adhesion was
prevented by increasing dose of seliciclib, possibly explaining the
lack of CAM-DR. The mechanism of the adhesion inhibition will
be addressed in our future studies. This direct effect of seliciclib on
adhesion suggests that seliciclib may be used as a single agent or in
combination with other potent drugs that display CAM-DR.
Moreover, we demonstrated that combination of seliciclib with
flavopiridol was highly effective in overcoming stromal-promoted
drug resistance.
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sensitivity to CDK inhibition that may proceed via several
mechanisms:
1. CCND over-expression is a postulated early pathogenetic event
in MM, the survival of this neoplasm depends on its expression.
Indeed, seliciclib-induced down regulation of CCND has been
shown by us as well as by others.
2. The seliciclib effect was not limited to CCND, it also
dramatically reduced the expression of p27. Within a normal
cell cycle, the reduction of both proteins accompanies the G1
to S transition. An additional response to seliciclib is an
increased expression of CCNE1, which is another marker for
S-phase entry. The entry to the S-phase may render the cells to
higher susceptibility to the cytotoxic effects of seliciclib.
3. The elevated expression of MCL1 is a poor prognostic marker
for Multiple Myeloma. Our results indicate that CDK
inhibition represses the expression of MCL1 both on the level
of transcription and protein stability. Elimination of this crucial
anti-apoptotic protein by anti-sense, has been shown to lead to
apoptosis [26,60,61].
4. CDK combined inhibition effectively targets MM and
overcomes microenvironment-produced resistance, therefore
potentially providing the rationale for CDK inhibition as part
of therapeutic strategy in myeloma.
Materials and Methods
Cells
Human multiple myeloma cell lines (hMMCLs) were obtained
from American Type Culture Collection (Rockille, MD, USA):
U266, ARH77, RPMI8226, NCI H929. CAG and were a kind gift
of Prof. Vlodavsky from Technion. hMMCLs were maintained in
RPMI 1640 supplemented with 10% non deactivated FCS, 0.4%
glucose, HEPES 10 mM, sodium pyruvate 1 mM and penicillin-
streptomycin and incubated at 37uC in a humidified incubator
under atmosphere of 5% CO2 and 95% air. NCI-H929 required
the addition of beta-meracptoethanol (0.0014%).
The bone marrow stromal cells (BMSCs) were isolated from the
BM-mononuclear cells (BM-MNC) by plate adherence. Briefly,
BM-MNC were re-suspended in 5 mL of MSC growth medium
(MGM) (MEMa supplemented with 20% fetal bovine serum and
1% 1006penicillin–streptomycin), transferred to a 25-cm
2 flask
and incubated overnight. On the next day, after the medium was
removed, the adhered cells were washed three times with PBS and
grown further in MGM. BMSCs were passaged after reaching
80% confluency by trypsinization.
Antibodies and Reagents
All antibodies were purchased from Santa-Cruz (Santa Cruz,
CA, U.S.A.). Tissue culture reagents were purchased from
GIBCO (Carlsbad, CA, USA). Seliciclib was purchased from
LKT Laboratories, Inc. (St. Paul, MN, USA) and dissolved in
dimethylsulfoxide (DMSO) as a stock solution of 100 mM.
Flavopiridol was purchased from Enzo Life Sciences (Farmingdale,
NY, USA). All other reagents were supplied by Sigma (Rehovot;
Israel).
SDS-PAGE, Western Blotting
Cells were lyzed in RIPA buffer (25mM Tris pH=7.6, 150 mM
NaCl, 1% NP40, 1% Sodium deoxycholate, 0.1% SDS) plus
protease inhibitor cocktail I and II and centrifuged at 10,000 xg
for 10 min. Extract supernatant corresponding to 50 mg was
loaded per lane. Following SDS-PAGE, the proteins were
transferred to nitrocellulose membranes and the membrane was
blocked with either 5% skim-milk or 3% BSA in 10 mM Tris,
150 mM NaCl for one hour at rT. Primary antibodies were
incubated overnight at 4uC, followed by multiple washes in TBS-
T. The appropriate horseradish peroxidase-conjugated secondary
antibodies were incubated in the blocking solution for one hour at
room temperature (rT), followed by multiple washes with TBS-T.
Chemiluminescence was detected using an ECL kit Pierce
(Rockford, IL, USA) in accordance with the manufacturer’s
protocol.
Real-Time RT-PCR
Total RNA was extracted from 2610
6 cells incubated in the
indicated conditions, using nucleospin RNA II Macherey-Nagel
(Duren, Germany) according to the manufacturer’s instructions.
The RNA was reverse transcribed using the High Capacity cDNA
RT Applied Biosystems (Foster City, CA, USA). Quantitative
PCR for human CCNE1 (NM_001238.2) was carried-out by
utilizing Taqman Assay on demand and the PCR master mix for
real-time, Applied Biosystems (Foster City, CA, USA). The PCR
products were produced and quantified in 7500 real time PCR
system, Applied Biosystems (Foster City, CA, USA).
Cell Viability Assay
Measurements of cell viability were performed by an MTT
assay which quantifies the reduction of MTT with metabolically
active cells. Cells were plated in 96-well plate and incubated in the
presence of increasing dose of seliciclib or DMSO for 3 days. Cells
were pulsed with MTT 5 mg/ml for 4 hours, followed by lysis with
10% SDS, 0.01 M HCl and incubation at 37uC over-night.
Absorbance was measured at a wave length of 570 nm using a
Molecular Devices spectrophotometer (Sunnyvale, CA, USA).
Cell Cycle Analysis
Human MMCL cells (0.5610
6) were cultured for the specified
times in the medium alone, DMSO or with 50 mM seliciclib. The
cells were harvested, washed with phosphate-buffered saline (PBS)
and fixed with 70% ethanol at –20uC over-night. Fixed cells were
treated with 50 mg/mL RNAse for 2 hours at 37uC and then
stained with propidium iodide; 50 mg/mL. Cell cycle profile was
determined by FACS analysis using BD FACS Calibur multicolor
flow cytometer Becton Dickenson (San Jose, CA, USA) and
analyzed using Cell quest Becton-Dickenson (San Jose, CA, USA).
The subdyploid DNA peak (subG1) representing apoptotic cells.
Annexin V Binding
The extent of apoptosis was evaluated by flow cytometric
analysis utilizing Annexin V staining. Annexin V binding to the
exposed phosphatidylserine (PS) at the cell surface occurs early
during the process of apoptosis. 1610
5 of control or seliciclib-
treated cells (50 mM for 4 hours) were stained with the
MEBCYTO kit of Annexin V-FITC MBL International (Woburn,
MA, USA) according to manufacturer’s protocol. The samples
were analyzed using flow cytometry within 1 hr to determine the
percentage of cells displaying Annexin V positivity.
Stable CCNE1-expressing Cell Line
RPMI H929 cells were transiently transfected using TransIT-
LT1 Mirus (Madison, WI, USA), with either pRCCMVCycE (a
kind gift of Prof. Doron Ginsburg, Bar-Ilan university), or
pRCCMV, according to the manufacturer’s suggested protocol.
Following the transfection the cells were placed in 1 mg/ml G418.
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selection media for over a month. CCNE1-expressing clones were
identified by immunoblotting.
Knock-down of CCNE1 with siRNA
ARH77 and RPMI8226 were transfected with 500 nM of
control non-target or specific CCNE1 siRNA (siGENOME
SMARTpool, obtained from Dharmacon, Thermo Fisher Scien-
tific, Lafayette, CO, USA) using Amaxa electroporation system
(Lonza, Basel, Switzerland) and Ingenio electroporation kit (Mirus)
according to the manufacture’s instructions. Forty eight hours
following the electroporation the cells were harvested for
immunoblotting and CCNE1 level were tested. In parallel, control
and siCCNE1-silenced cells were exposed to elevated amounts of
seliciclib for additional 48 hours and their viability was then tested
using MTT method.
Adhesion Assay
Fibronectin (FN) or BSA-coated plates were prepared by
coating 96-well plates with either (40 mg/ml) of soluble FN or
bovine serum albumin (BSA), followed by incubation at 37uC for 2
hours decanting of the liquid and evaporation overnight in a
biological hood. Cells were loaded into the coated-plates and
incubated for one hour at a humidified incubator at 37uC.
Seliciclib-treated cells were initially incubated on BSA-coated
plates for one hour and then transferred to FN-coated plates.
Unattached cells were removed by washing three times with serum
free RPMI media, and fixed with 70% methanol for 10 min at rT.
Cell staining was carried out by incubation for 10 minutes at rT
with 0.02% crystal violet/0.2% ethanol solution, followed by
washes with H2O. Solubilization of the stained cells was completed
by addition of 2% SDS for 30 minutes at rT. Absorbance was read
at a wave length of 550 nm on a spectrophotometer Power-
wave300 Bio-Tek Instruments Inc. (Winooski, VT, USA).
Images of cells were captured by an Olympus 2X70 microscope
utilizing DP controller software Olympus (Hamburg, Germany).
Statistics
Statistical analysis was carried out by the student’s t-test. A p-
value less than 0.05 was considered to be statistically significant.
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